Transcatheter mitral valve repair with MitraClip: comparison of NT, NTr, and XTr Devices
Nicola Corcione,Paolo Ferraro,Filippo Finizio,Michele Cimmino,Michele Albanese,Giuseppe Biondi-Zoccai,Paolo Denti,Antonio Popolo Rubbio,Antonio L Bartorelli,Annalisa Mongiardo,Salvatore Giordano,Francesco De Felice,Marianna Adamo,Matteo Montorfano,Cesare Baldi,Giuseppe Tarantini,Francesco Giannini,Federico Ronco,Ida Monteforte,Emmanuel Villa,Maurizio Ferrario,Luigi Fiocca,Fausto Castriota,Angelo Squeri,Corrado Tamburino,Francesco Bedogni,Arturo Giordano
DOI: https://doi.org/10.25270/jic/24.00020
Abstract:Objectives: Transcatheter edge-to-edge repair (TEER) has become an established minimally invasive treatment for significant mitral regurgitation. Ongoing refinements and the availability of different clipping devices have expanded the indications for and effectiveness of TEER, but comprehensive comparative data on this issue are lacking. In this study, we compared NT, NTr, and XTr MitraClip devices (Abbot) for TEER. Methods: Details on patient, imaging, and procedural details, as well as short- and long-term outcomes, were sought from a national prospective clinical registry on TEER with MitraClip. The primary outcome of interest was discharge after procedural success without major clinical complications. Results: A total of 2236 patients were included, 1228 (54.9%) in whom NT implantation only was attempted, 233 (10.4%) in whom NTr but not XTr implantation was attempted, and 775 (34.7%) in whom XTr implantation was attempted. Clinical and imaging features differed substantially across the groups, reflecting expanding indications with NTr and XTr devices. In-hospital outcomes were largely similar among the 3 groups, including death. Long-term unadjusted estimates of effect showed significant differences in several outcomes, including death, rehospitalization, and their composite, which demonstrated that NT was associated with more unfavorable outcomes compared with the other devices (all P less than .05). However, most differences depended on baseline features, as adjusted analysis showed no significant differences for early as well as long-term outcomes, including long-term death, rehospitalization, and their composite (all P greater than .05). Conclusions: New-generation MitraClip devices are associated with favorable procedural and clinical outcomes, despite being used in patients with more adverse features, when compared with patients treated with previous devices.